Head to Head Survey: Kymera Therapeutics (NASDAQ:KYMR) and Candel Therapeutics (NASDAQ:CADL)

Candel Therapeutics (NASDAQ:CADL) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability.

Risk & Volatility

Candel Therapeutics has a beta of -0.81, indicating that its share price is 181% less volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.28, indicating that its share price is 128% more volatile than the S&P 500.

Valuation & Earnings

This table compares Candel Therapeutics and Kymera Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18 million	($0.71)	-7.01
Kymera Therapeutics	$39.21 million	176.83	-$311.35 million	($3.68)	-23.08

Candel Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

13.9% of Candel Therapeutics shares are held by institutional investors. 16.6% of Candel Therapeutics shares are held by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Candel Therapeutics and Kymera Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-51.44%	-36.31%
Kymera Therapeutics	-794.04%	-28.71%	-25.13%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Candel Therapeutics and Kymera Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1	2	5	0	2.50
Kymera Therapeutics	1	0	20	1	2.95

Candel Therapeutics currently has a consensus price target of $18.00, suggesting a potential upside of 261.45%. Kymera Therapeutics has a consensus price target of $118.90, suggesting a potential upside of 40.00%. Given Candel Therapeutics’ higher probable upside, equities analysts clearly believe Candel Therapeutics is more favorable than Kymera Therapeutics.

About Candel Therapeutics

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

About Kymera Therapeutics

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.